

Dr. James M. Veal
746 West Solana Circle
Solana Beach, CA 92075
919-741-8604 (mobile)
jveal8916@gmail.com

Overview:

Chief Scientific Officer with a demonstrated record of successful drug discovery at both large pharma and biotech. Expertise in the discovery of small molecule inhibitors for the treatment of diseases, including cancer and inflammatory disorders. Experienced in the oversight and management of drug discovery programs from target evaluation stage to optimization of inhibitors and through IND filing and entry into clinical trials. Proven ability to lead in both supervisory and team relationships and able to develop a company culture that enables successful team execution. Good communication skills with significant experience in presenting as part of board meetings, investor outreach, and to large pharma evaluation teams. Co-inventor on multiple patents and co-author on multiple scientific publications.

Professional Experience

858 Therapeutics, San Diego, CA

2019 - Present Co-founder and Chief Scientific Officer

- Member of 858 Therapeutics senior management team
- Managed cross-functional drug discovery efforts leading to the discovery of ETX-19477 as a Clinical Candidate for the inhibition of PARG and treatment of cancer
- Managed cross-functional drug discovery efforts leading to the discovery of ETX-20052 as a Development Candidate for the inhibition of QPCT/L
- Developed and managed annual research budgets, including both internal and external CRO activities
- Co-inventor of ETX-19477 and ETX-20052
- Presented 858 Therapeutics research efforts to multiple venture capital groups leading to a Series A2 financing round (Versant Ventures, NEA, Logos, and Cormorant)
- Key member of team that prepared IND submission documents for ETX-19477

Jecure Therapeutics, San Diego, CA (acquired by Genentech in 2018)

2015 - 2019 Co-founder and Chief Scientific Officer

- Member of Jecure senior management team
- Managed cross-functional drug discovery efforts leading to the discovery of JT-194 and JT-522 as Development Candidates for the inhibition of NLRP3 and treatment of inflammatory disorders
- Developed and managed annual research budgets, including both internal and external CRO activities

Dr. James M. Veal

- Co-inventor of GDC-2394 (JT-522)
- Presented Jecure research efforts to venture capital groups, leading to a Series B termsheet
- Primary member of the team that interacted with Genentech and negotiated the acquisition of Jecure

Quanticel Pharmaceuticals Inc., San Francisco, CA (acquired by Celgene in 2015)

2012 - 2015 Distinguished Research Fellow

2015 Executive Director, Celgene Quanticel Research (Subsidiary of Celgene)

- Member of Quanticel executive management team
- Senior leadership role in discovery research efforts
- Presented Quanticel research efforts to senior level Celgene management teams as part of regular Joint Research Committee portfolio reviews and Celgene Development Candidate reviews
- Co-inventor of trotabresib (CC-90010, BRD4 inhibitor) and pulrodestat (CC-90011, LSD1 inhibitor), currently in clinical trials
- Key member of team that prepared IND submission documents for CC-90010 and CC-90011
- Supervised biochemistry and cell pharmacology groups

Pamlico Pharmaceutical Inc., Research Triangle Park, NC

2009 - 2011 Vice President of Research

- Member of founding group of research scientists and supervised formation of discovery team and lab start-up
- Led cross-functional research efforts across the organization including Hedgehog, Nedd8, TGR5, and GPR120 programs
- Co-inventor of Hedgehog inhibitor, SHR-1539 (PI-722), which advanced into clinical trials in China

Serenex, Inc., Durham, NC (acquired by Pfizer in 2008)

2005 - 2008 Senior Director of Structural Chemistry and Informatics

2003 - 2005 Director of Structural Chemistry and Informatics

- Made essential contributions to hit discovery and lead optimization efforts across multiple research programs including HSP90, DHFR, and Aurora kinase
- Primary leadership role in Serenex Hsp90 discovery effort; co-inventor for SNX-5422 which advanced to phase 2 clinical trials in cancer
- One of 3 senior leaders of Serenex research team that successfully guided Hsp90 program from initiation to IND
- Co-inventor on Hsp90 and DHFR inhibitor patents
- Guided analytical chemistry group's role in pharmacokinetic analysis including acute and dose range finding toxicokinetic studies for Hsp90 IND filing

- Responsible for analytical chemistry, computational chemistry, and informatics groups; led mass spectrometry component of proteomics effort
- Extensively presented Serenex research efforts to external investors and large pharma partners
- Developed advanced chemoinformatic techniques used in evaluating chemical libraries for proteomics based screening platform
- Designed and led implementation of an advanced chemical registry and biology records database that was specialized for proteomics data searching and interfacing with LIMS systems workflow

GlaxoSmithKline, Research Triangle Park, NC

2000 - 2003 Senior Research Investigator

1996 - 2000 Research Investigator II

1992 - 1996 Research Investigator I

1991 - 1992 Postdoctoral Fellow in computational chemistry

- Made essential contributions to hit discovery and lead optimization efforts across multiple research programs
- Recognized leader in modeling of protein kinases, GPCRs, and other macromolecules
- Chemistry chair of committee responsible for evaluating new kinase drug targets for entire GSK international research
- Integral member of discovery teams for 3 compounds that advanced to clinical trials: pazopanib (VEGR2/PDGFR inhibitor), lapatinib (HER2/EGFR inhibitor), and GSK461364 (PLK1 inhibitor)
- Co-inventor on Votrient (pazopanib) and PLK1 inhibitor patents
- Co-inventor for 2 additional clinical candidates (CDK2 and P38) discovered at Glaxo Wellcome
- Supervised multiple senior computational chemists
- Designed and managed acquisition of chemical screening libraries
- Expert in using structural aided drug discovery techniques
- Expert in developing software applications (C, C++, Java, Perl, PHP, Python, HTML, SQL)

Education

Ph.D. in Molecular Biophysics

- The Florida State University, The Institute of Molecular Biophysics, Tallahassee, FL
- Major Professor: Randolph L. Rill
- Dissertation: Interaction of DNA with the complex bis-(1,10-phenanthroline) copper(I)
- James S. Fisher Award for outstanding contribution by a graduate science student
- Formally trained as physical chemist, computational chemist, and NMR spectroscopist

B.A. in Chemistry with Specialization in Biological Sciences

- Duke University, Durham, NC
- Cum Laude, Chemical Honor Society

Activities

- Memberships in American Chemical Society and American Association for the Advancement of Science
- Reviewer for Journal of the American Chemical Society, Proceedings of the National Academy of Sciences, Journal of Physical Organic Chemistry, Biochemistry, Biorganic and Medicinal Chemistry Letters

Patent Applications

WO/2024/020517; 3-(6-Pyridin-3-yl)-2-[4-(4-Methyl-4H-1,2,4-Triazol-3-yl)Piperidin-1-yl]Benzonitrile Derivatives and Similar Compounds as QPCTL and QPCT Inhibitors for the Treatment of Cancer; 858 Therapeutics, Inc.; **Veal, JM**; Stafford, JA; Karanewsky, DS; Herath, S.

WO/2023/224998; Inhibitors of PARG; 858 Therapeutics, Inc.; **Veal, JM**; Stafford, JA; Karanewsky, DS; Herath, S.

WO/2023/129933; 6,6-Fused Heterocyclic Compounds as METTL3 Inhibitors; 858 Therapeutics, Inc.; Cheruvallath, ZS; **Veal, JM**; Stafford, JA; McBride, C.

WO/2020/018970; Sulfonylurea Compounds as Inhibitors of Interleukin-1 Activity; Jecure Therapeutics, Inc.; Stafford, JA; **Veal, JM**; Trzoss, LL; McBride, C; Pastor, RM; Staben, ST; Stivala, C; Volgraf, M.

WO/2018/136890; Chemical Compounds as Inhibitors of Interleukin-1 Activity; Jecure Therapeutics, Inc.; Stafford, JA; **Veal, JM**; Trzoss, LL; McBride, C.

WO/2018/075796; Bromodomain Inhibitor; Celgene Quanticel Research, INC; Betancort, JM; Stafford, JA; Stansfield, R; **Veal, JM**.

WO/2017/184491; Histone Demethylase Inhibitors; Celgene Quanticel Research, Inc.; Nie, Z; Stafford, JA; **Veal, JM**; Wallace, MB.

WO/2017/184462; Therapeutic Compounds; Celgene Quanticel Research, Inc.; Bennett, MJ; Betancort, JM; Boloor, A; Kanouni, T; Stafford, JA; **Veal, JM**; Wallace, MB.

WO/2017/161012; Histone Demethylase Inhibitors; Celgene Quanticel Research, Inc.; Boloor, A; Kanouni, T; Stafford, JA; **Veal, JM**; Wallace, MB.

WO/2017/161033; Histone Demethylase Inhibitors; Celgene Quanticel Research, Inc.; Chen, YK; Nie, Z; Stafford, JA; **Veal, JM**.

WO/2017/079670; Compositions Comprising an Inhibitor of Lysine Specific Demethylase-1; Celgene Quanticel Research, Inc.; Chen, YK; Kanouni, T; Kaldor, SW; Stafford, JA; **Veal, JM**; Tavares Greco, PA; Kreilein, MM.

WO/2016/172618; Bromodomain Inhibitor; Celgene Quanticel Research, Inc.; Betancort, JM; Stafford, JA; Stansfield, R; **Veal, JM.**

WO/2016/168682; Bromodomain Inhibitor; Celgene Quanticel Research, Inc.; Bennett, MJ; Betancort, JM; Bolor, A; Kaldor, SW; Stafford, JA; **Veal, JM.**

WO/2016/044429; Histone Demethylase Inhibitors; Celgene Quanticel Research, Inc.; Bolor, A; Kanouni, T; Stafford, JA; **Veal, JM;** Wallace, MB.

WO/2016/044342; Histone Demethylase Inhibitors; Celgene Quanticel Research, Inc.; Chen, YK; Nie, Z; Stafford, JA; **Veal, JM.**

WO/2016/037005; Inhibitors of Lysine Specific Demethylase-1; Celgene Quanticel Research, Inc.; Chen, YK; Kanouni, T; Stafford, JA; **Veal, JM.**

WO/2016/003917; Inhibitors of Lysine Specific Demethylase1; Quanticel Pharmaceuticals, Inc.; Chen, YK; Kanouni, T; Nie, Z; Stafford, JA; **Veal, JM.**

WO/2016/004105; Inhibitors of Lysine Specific Demethylase1; Quanticel Pharmaceuticals, Inc.; Chen, YK; Kanouni, T; Nie, Z; Stafford, JA; **Veal, JM.**

WO/2015/200843; Inhibitors of Lysine Specific Demethylase1; Quanticel Pharmaceuticals, Inc.; Chen, YK; Kanouni, T; Stafford, JA; **Veal, JM.**

WO/2015/168466; Inhibitors of Lysine Specific Demethylase1; Quanticel Pharmaceuticals, Inc.; Chen, YK; Kanouni, T; Kaldor, SW; Stafford, JA; **Veal, JM.**

WO/2015/089192; Inhibitors of Lysine Specific Demethylase1; Quanticel Pharmaceuticals, Inc.; Chen, YK; Kanouni, T; Kaldor, SW; Stafford, JA; **Veal, JM.**

WO/2015/058160; Bromodomain Inhibitors; Quanticel Pharmaceuticals, Inc.; Bennett, MJ; Betancort, JM; Bolor, A; Kaldor, SW; Stafford, JA; **Veal, JM.**

WO/2014/151945; Histone Demethylase Inhibitors; Quanticel Pharmaceuticals, Inc.; Kanouni, T; Nie, Z; Stafford, JA; **Veal, JM.**

WO/2014/151106; Histone Demethylase Inhibitors; Quanticel Pharmaceuticals, Inc.; Kanouni, T; Stafford, JA; **Veal, JM;** Wallace, MB.

WO/2014/100463; Histone Demethylase Inhibitors; Quanticel Pharmaceuticals, Inc.; Kanouni, T; Stafford, JA; **Veal, JM;** Wallace, MB.

WO/2014/100818; Histone Demethylase Inhibitors; Quanticel Pharmaceuticals, Inc.; Chen, YK; Kanouni, T; Stafford, JA; **Veal, JM;** Wallace, MB.

WO/2014/089364; Histone Demethylase Inhibitors; Quanticel Pharmaceuticals, Inc.; Nie, Z; Kanouni, T; Stafford, JA; **Veal, JM;** Wallace, MB.

WO/2008/130879; Tetrahydroindole and Tetrahydroindazole Derivatives; Serenex, Inc.; Huang, KH; Ommen, AJ; Barta, TE; Hughes, PF; **Veal, JM**; Ma, W; Smith, E; Woodward, AR; McCall, SW.

WO/2008/045529; Purine and Pyrimidine Derivatives for Treatment of Cancer and Inflammatory Diseases; Serenex, Inc.; Huang, KH; **Veal, J**.

WO/2008/024981; Purine, Pyrimidine, and Azaindole Derivatives; Serenex, Inc.; Huang, KH; **Veal, J**; Smith, ED; Ma, W.

WO/2008/024980; Pyrrole, Thiophene, Furan, Imidazole, Oxazole, and Thiazole Derivatives; Serenex, Inc.; Huang, KH; Hall, SE; **Veal, J**.

WO/2008/024978; Benzene, Pyridine, and Pyridazine Derivatives; Serenex, Inc.; Huang, KH; Mangette, J; Barta, T; Hughes, P; Hall, SE; **Veal, J**.

WO/2008/024977; Isoquinoline, Quinazoline and Phthalazine Derivatives; Serenex, Inc.; Huang, KH; **Veal, J**; Barta, T; Smith, ED; Ma, W; Ommen, A.

WO/2008/024974; Pyrimidine and Pyrazine Derivatives; Serenex, Inc.; Huang, KH; Smith, ED; **Veal, J**.

WO/2008/024970; Benzene, Pyridine, and Pyridazine Derivatives; Serenex, Inc.; Huang, KH; Hughes, P; Ma, W; Ommen, A; Woodward, A; **Veal, J**; Barta, T.

WO/2008/024963; Benzene, Pyridine, and Pyridazine Derivatives; Serenex, Inc.; Huang, KH; Barta, T; Smith, ED; Hall, SE; **Veal, J**.

WO/2008/024961; Dihydropyridazine, Tetrahydropyridine, Chromanone, and Dihydronaphthalenone Derivatives as Heat-shock Protein 90 Inhibitors; Serenex, Inc.; Huang, KH; Hughes, P; Barta, T; **Veal, J**.

WO/2007/101156; Cyclohexylamino, Benzene, Pyridine, and Pyridazine Derivatives; Serenex, Inc.; Huang, KH; Eaves, J; **Veal, J**; Hall, SE; Barta, T; Hanson, GJ.

WO/2007/035620; Carbazole Derivatives; Serenex, Inc.; Hanson, GJ; Barta, TE; Geng, L; Huang, KH; **Veal, J**.

WO/2006/091963; Tetrahydroindolone and Tetrahydroindazolone Derivatives; Serenex, Inc.; Huang, KH; Eaves, J; **Veal, J**; Barta, T; Geng, L; Hinkley, L; Hanson, G.

WO/2006/014706; Methotrexate Derivatives Useful for Treating Cancer and Arthritis; Serenex, Inc.; Hanson, GJ; Barta, TE; **Veal, JM**; Ware, RW.

WO/2005/011681; Chemical Compounds; Smithkline Beecham Corporation; Drewry, DH; Linn, JA; **Veal, JM**.

WO/2004/014899; Thiophene Compounds; Smithkline Beecham Corporation; Andrews, III, CW; Cheung, M; Davis-Ward, RG; Drewry, DH; Emmitte, KA; Hubbard, RD; Kuntz, KW; Linn, JA; Mook, RA; Smith, GK; **Veal, JM**.

WO/2004/009602; Pyrazolopyrimidines as Kinase Inhibitors; Smithkline Beecham Corporation; Brown, ML; Cheung, M; Dickerson, SH; Garrido, DM; Mills, WY; Miyazaki, Y; Peat, AJ; Peckham, GE, Poole, J; Smalley, TL; Thomson, SA; **Veal, JM**; Wilson, JL.

WO/2004/009596; Pyrazolopyrimidines as Kinase Inhibitors; Smithkline Beecham Corporation; Brown, ML; Cheung, M; Dickerson, SH; Drewry, DH; Lackey, KE; Peat, AJ; Thomson, SA; **Veal, JM**; Wilson, JL.

US/2004/002145; Crystal Structure of Liganded cFMS Kinase Domain; Glaxo Group Limited; Shewchuk LM; Hassell, AM; Holmes, WD; **Veal, JM**; Emerson, HK; Musso, DL; Chamberlain, SD; Peckham, GE.

WO/2003/080125; Benzimidazoles and Their Use as Mitogen-activated- and Rho-kinase Inhibitors; Glaxo Group Limited; Alberti, MJ; Garland, S; Jung, DK; **Veal, JM**; Witherington, J.

WO/2003/066601; Pyrimidine Compounds; Smithkline Beecham Corporation; Cheung, M; Nailor, KE; Sammond, DM; **Veal, JM**.

WO/2003/051886; Pyrazolopyridazine Derivatives; Smithkline Beecham Corporation; Harris, PA; Jung, DK; Peel, MR; Reno, MJ; Rheault, TR; Badiang, JG.; Stevens, KL; **Veal, JM**; Dickerson, SH; Tavares, FX.

WO/2002/059110; Pyrimidineamines as Angiogenesis Modulators; Glaxo Group Limited; Boloor, A; Cheung, M; Davis, R; Harris, PA; Hinkle, K; Mook, RA; Stafford, JA; **Veal, JM**.

WO/2002/044156; Benzimidazole Derivatives Useful as Tie-2 and/or Vegfr-2 Inhibitors; Glaxo Group Limited; Cheung, M; Harris, PA; Hasegawa, M; Ida, S; Kano, K; Nishigaki, N; Sato, H; **Veal, JM**; Washio, Y; West, RI.

WO/2002/016359; Fused Pyrazole Derivatives Being Protein Kinase Inhibitors; Glaxo Group Limited; Alberti, MJ; Baldwin, IR; Cheung, M; Cockerill, S; Flack, S; Harris, PA; Jung, DK; Peckham, G; Peel, MR; Stanford, JB; Stevens, K; **Veal, JM**.

WO/2000/055159; Substituted Aza-oxindole Derivatives; Glaxo Group Limited; Harris, PA; Kuyper, LF; Lackey, KE; **Veal, JM**.

WO/1999/015500; Substituted Oxindole Derivatives as Protein Tyrosine Kinase and as Protein Serine/threonine Kinase Inhibitors; Glaxo Group Limited; Davis, ST; Dickerson, SH; Frye, SV; Harris, PA; Hunter, RN; Kuyper, LF; Lackey, KE; Luzzio, MJ; **Veal, JM**; Walker, DH.

WO/1999/010325; Benzylidene-1,3-dihydro-indol-2-one Derivatives as Receptor Tyrosine Kinase Inhibitors, Particularly of Raf Kinases; Glaxo Group Limited; Mcnutt, RW; Jung, DK; Harris, PA; Hunter, RN; **Veal, JM**; Dickerson, S; Lackey, KE; Peel, MR.

Publications (* indicates corresponding author)

Ambrus-Aikelin G, Takeda K, Joetham A, Lazic M, Povero D, Santini AM, Pranadinata R, Johnson CD, McGeough MD, Beasley FC, Stansfield R, McBride C, Trzoss L, Hoffman HM, Feldstein AE, Stafford JA, **Veal JM**, Bain G, Gelfand EW. JT002, a small molecule inhibitor of the NLRP3 inflammasome for the treatment of autoinflammatory disorders. Sci Rep. 2023 Aug 19;13(1):13524. PMID: 37598239.

Povero D, Lazic M, McBride C, Ambrus-Aikelin G, Stansfield R, Johnson CD, Santini AM, Pranadinata RF, McGeough MD, Stafford JA, Hoffman HM, Feldstein AE, **Veal JM**, Bain G. Pharmacology of a Potent and Novel Inhibitor of the NOD-Like Receptor Pyrin Domain-Containing Protein 3 (NLRP3) Inflammasome that Attenuates Development of Nonalcoholic Steatohepatitis and Liver Fibrosis. *J Pharmacol Exp Ther*. 2023 Aug;386(2):242-258. PMID: 37308266.

McBride C, Trzoss L, Povero D, Lazic M, Ambrus-Aikelin G, Santini A, Pranadinata R, Bain G, Stansfield R, Stafford JA, **Veal J**, Takahashi R, Ly J, Chen S, Liu L, Nespi M, Blake R, Katewa A, Kleinheinz T, Sujatha-Bhaskar S, Ramamoorthi N, Sims J, McKenzie B, Chen M, Ultsch M, Johnson M, Murray J, Ciferri C, Staben ST, Townsend MJ, Stivala CE. Overcoming Preclinical Safety Obstacles to Discover (S)-N-((1,2,3,5,6,7-Hexahydro- s-indacen-4-yl)carbamoyl)-6-(methylamino)-6,7-dihydro-5 H-pyrazolo[5,1- b][1,3]oxazine-3-sulfonamide (GDC-2394): A Potent and Selective NLRP3 Inhibitor: A Potent and Selective NLRP3 Inhibitor. *J Med Chem*. 2022 Nov 10;65(21):14721-14739. PMID: 36279149.

Kanouni T, Severin C, Cho RW, Yuen NY, Xu J, Shi L, Lai C, Del Rosario JR, Stansfield RK, Lawton LN, Hosfield D, O'Connell S, Kreilein MM, Tavares-Greco P, Nie Z, Kaldor SW, **Veal JM**, Stafford JA, Chen YK. Discovery of CC-90011: A Potent and Selective Reversible Inhibitor of Lysine Specific Demethylase 1 (LSD1). *J Med Chem*. 2020 Dec 10;63(23):14522-14529. PMID: 33034194.

Nie Z, Shi L, Lai C, Severin C, Xu J, Del Rosario JR, Stansfield RK, Cho RW, Kanouni T, **Veal JM**, Stafford JA, Chen YK. Structure-based design and discovery of potent and selective lysine-specific demethylase 1 (LSD1) inhibitors. *Bioorg Med Chem Lett*. 2019 Jan 1;29(1):103-106. PMID: 30409536.

Bennett MJ, Wu Y, Bloor A, Matuszkiewicz J, O'Connell SM, Shi L, Stansfield RK, Del Rosario JR, **Veal JM**, Hosfield DJ, Xu J, Kaldor SW, Stafford JA, Betancort JM. Design, synthesis and biological evaluation of novel 4-phenylisoquinolinone BET bromodomain inhibitors. *Bioorg Med Chem Lett*. 2018 Jun 1;28(10):1811-1816. PMID: 29657099.

Nie Z, Shi L, Lai C, O'Connell SM, Xu J, Stansfield RK, Hosfield DJ, **Veal JM**, Stafford JA. Structure-based design and discovery of potent and selective KDM5 inhibitors. *Bioorg Med Chem Lett*. 2018 May 15;28(9):1490-1494. PMID: 29627262.

Chen YK, Bonaldi T, Cuomo A, Del Rosario JR, Hosfield DJ, Kanouni T, Kao SC, Lai C, Lobo NA, Matuszkiewicz J, McGeehan A, O'Connell SM, Shi L, Stafford JA, Stansfield RK, **Veal JM**, Weiss MS, Yuen NY, Wallace MB. Design of KDM4 Inhibitors with Antiproliferative Effects in Cancer Models. *ACS Med Chem Lett*. 2017 Jul 27;8(8):869-874. PMID: 28835804.

Carlson DA, Franke AS, Weitzel DH, Speer BL, Hughes PF, Hagerty L, Fortner CN, **Veal JM**, Barta TE, Zieba BJ, Somlyo AV, Sutherland C, Deng JT, Walsh MP, MacDonald JA, Haystead TA. Fluorescence linked enzyme chemoproteomic strategy for discovery of a potent and selective DAPK1 and ZIPK inhibitor. *ACS Chem Biol*. 2013 Dec 20;8(12):2715-23. PMID: 24070067.

Huang KH, Barta TE, Rice JW, Smith ED, Ommen AJ, Ma W, **Veal JM**, Fadden RP, Barabasz AF, Foley BE, Hughes PF, Hanson GJ, Markworth CJ, Silinski M, Partridge JM, Steed PM, Hall SE. Discovery of novel aminoquinazolin-7-yl 6,7-dihydro-indol-4-ones as potent, selective inhibitors of heat shock protein 90. *Bioorg Med Chem Lett*. 2012 Apr 1;22(7):2550-4. PMID: 22386527.

Fadden P, Huang KH, **Veal JM***, Steed PM, Barabasz AF, Foley B, Hu M, Partridge JM, Rice J, Scott A, Dubois LG, Freed TA, Silinski MA, Barta TE, Hughes PF, Ommen A, Ma W, Smith ED, Spangenberg AW, Eaves J, Hanson GJ, Hinkley L, Jenks M, Lewis M, Otto J, Pronk GJ, Verleysen K, Haystead TA, Hall SE. "Application of chemoproteomics to drug discovery: identification of a clinical candidate targeting hsp90. Chem Biol." 2010 Jul 30;17(7):686-94. PMID: 20659681.

Putcha P, Danzer KM, Kranich LR, Scott A, Silinski M, Mabbett S, Hicks CD, **Veal JM**, Steed PM, Hyman BT, McLean PJ. "Brain-permeable small-molecule inhibitors of Hsp90 prevent alpha-synuclein oligomer formation and rescue alpha-synuclein-induced toxicity." J Pharmacol Exp Ther. 2010 Mar;332(3):849-57. PMID: 19934398.

Veal, J. M. (2009) "Practical Use of Computational Chemistry in Kinase Drug Discovery", in *Kinase Inhibitor Drugs* (eds R. Li and J. A. Stafford), John Wiley & Sons, Inc., Hoboken, NJ, USA. doi: 10.1002/9780470524961.ch16

Huang KH, **Veal JM**, Fadden RP, Rice JW, Eaves J, Strachan JP, Barabasz AF, Foley BE, Barta TE, Ma W, Silinski MA, Hu M, Partridge JM, Scott A, DuBois LG, Freed T, Steed PM, Ommen AJ, Smith ED, Hughes PF, Woodward AR, Hanson GJ, McCall WS, Markworth CJ, Hinkley L, Jenks M, Geng L, Lewis M, Otto J, Pronk B, Verleysen K, Hall SE. "Discovery of Novel 2-Aminobenzamide Inhibitors of Heat Shock Protein 90 as Potent, Selective and Orally Active Antitumor Agents." J Med Chem. 2009 Jul 23;52(14):4288-305. PMID: 19552433.

Barta TE, Barabasz AF, Foley BE, Geng L, Hall SE, Hanson GJ, Jenks M, Ma W, Rice JW, **Veal J.** "Novel carbazole and acyl-indole antimitotics." Bioorg Med Chem Lett. 2009 Jun 1;19(11):3078-80. PMID: 19394222.

Rice JW, **Veal JM**, Barabasz A, Foley B, Fadden P, Scott A, Huang K, Steed P, Hall S. "Targeting of multiple signaling pathways by the Hsp90 inhibitor SNX-2112 in EGFR resistance models as a single agent or in combination with erlotinib." Oncol Res. 2009;18(5-6):229-42. PMID: 20225761.

Rice JW, **Veal JM***, Fadden P, Barabasz AF, Partridge JM, Barta TE, Dubois LG, Huang KH, Mabbett SR, Silinski MA, Steed PM, Hall SE. "Small Molecule Inhibitors of Hsp90 Potently Impact Inflammatory Disease Pathways and Show Activity in Models for Rheumatoid Arthritis." Arthritis Rheum. 2008 Dec;58(12):3765-75. PMID: 19035474.

Stevens KL, Reno MJ, Alberti JB, Price DJ, Kane-Carson LS, Knick VB, Shewchuk LM, Hassell AM, **Veal JM**, Davis ST, Griffin RJ, Peel MR. Synthesis and evaluation of pyrazolo[1,5-b]pyridazines as selective cyclin dependent kinase inhibitors. Bioorg Med Chem Lett. 2008 Nov 1;18(21):5758-62. PMID: 18835709.

Harris PA, Bloor A, Cheung M, Kumar R, Crosby RM, Davis-Ward RG, Epperly AH, Hinkle KW, Hunter RN, Johnson JH, Knick VB, Laudeman CP, Luttrell DK, Mook RA, Nolte RT, Rudolph SK, Szewczyk JR, Truesdale AT, **Veal JM**, Wang L, Stafford JA. "Discovery of N4-(2,3-Dimethyl-2H-indazol-6-yl)-N4-methyl-N2-(4-methyl-3-sulfonamidophenyl)-2,4-pyrimidinediamine (Pazopanib), a Novel and Potent VEGFR Inhibitor." J Med Chem. 2008 Aug 14;51(15):4632-40. PMID: 18620382.

Barta TE, **Veal JM***, Rice JW, Partridge JM, Fadden RP, Ma W, Jenks M, Geng L, Hanson GJ, Huang KH, Barabasz AF, Foley BE, Otto J, Hall SE. "Discovery of Benzamide tetrahydro-4H carbazol-4-ones as Novel

Small Molecule Inhibitors of Hsp90." Bioorg Med Chem Lett. 2008 Jun 15;18(12):3517-21. PMID: 18511277

Hasegawa M, Nishigaki N, Washio Y, Kano K, Harris PA, Sato H, Mori I, West RI, Shibahara M, Toyoda H, Wang L, Nolte RT, **Veal JM**, Cheung M. "Discovery of Novel Benzimidazoles as Potent Inhibitors of TIE-2 and VEGFR-2 Tyrosine Kinase Receptors." J Med Chem. 2007 Sep 6;50(18):4453-70. PMID: 17676829

Stevens KL, Jung DK, Alberti MJ, Badiang JG, Peckham GE, **Veal JM**, Cheung M, Harris PA, Chamberlain SD, Peel MR. "Pyrazolo[1,5-a]pyridines as p38 kinase inhibitors." Org Lett. 2005 Oct 13;7(21):4753-6. PMID: 16209527

Sammond DM, Nailor KE, **Veal JM**, Nolte RT, Wang L, Knick VB, Rudolph SK, Truesdale AT, Nartey EN, Stafford JA, Kumar R, Cheung M. "Discovery of a novel and potent series of dianilinopyrimidineurea and urea isostere inhibitors of VEGFR2 tyrosine kinase." Bioorg Med Chem Lett. 2005 Aug 1;15(15):3519-23. PMID: 15990302

Harris PA, Cheung M, Hunter RN 3rd, Brown ML, **Veal JM**, Nolte RT, Wang L, Liu W, Crosby RM, Johnson JH, Epperly AH, Kumar R, Luttrell DK, Stafford JA. "Discovery and evaluation of 2-anilino-5-aryloxazoles as a novel class of VEGFR2 kinase inhibitors." J Med Chem. 2005 Mar 10;48(5):1610-9. PMID: 15743202

Kinases Chapter Authors: Jerry L. Adams, **James Veal**, Lisa Shewchuk. *Methods and Principles in Medicinal Chemistry: Protein Crystallography in Drug Discovery, Kinases*, © 2004 Wiley-VCH Verlag GmbH & Co. KGaA

Bramson HN, Corona J, Davis ST, Dickerson SH, Edelstein M, Frye SV, Gampe RT Jr, Harris PA, Hassell A, Holmes WD, Hunter RN, Lackey KE, Lovejoy B, Luzzio MJ, Montana V, Rocque WJ, Rusnak D, Shewchuk L, **Veal JM**, Walker DH, Kuyper LF. "Oxindole-based inhibitors of cyclin-dependent kinase 2 (CDK2): design, synthesis, enzymatic activities, and X-ray crystallographic analysis." J Med Chem. 2001 Dec 6;44(25):4339-58. PMID: 11728181

Lackey K, Cory M, Davis R, Frye SV, Harris PA, Hunter RN, Jung DK, McDonald OB, McNutt RW, Peel MR, Rutkowske RD, **Veal JM**, Wood ER. "The discovery of potent cRaf1 kinase inhibitors." Bioorg Med Chem Lett. 2000 Feb 7;10(3):223-6. PMID: 10698440

Shewchuk L, Hassell A, Wisely B, Rocque W, Holmes W, **Veal J**, Kuyper LF. "Binding mode of the 4-anilinoquinazoline class of protein kinase inhibitor: X-ray crystallographic studies of 4-anilinoquinazolines bound to cyclin-dependent kinase 2 and p38 kinase." J Med Chem. 2000 Jan 13;43(1):133-8. PMID: 10633045

Kiefer LL, **Veal JM**, Mountjoy KG, Wilkison WO. "Melanocortin receptor binding determinants in the agouti protein." Biochemistry. 1998 Jan 27;37(4):991-7. PMID: 9454589

Shi PY, Brinton MA, **Veal JM**, Zhong YY, Wilson WD. "Evidence for the existence of a pseudoknot structure at the 3' terminus of the flavivirus genomic RNA." Biochemistry. 1996 Apr 2;35(13):4222-30. PMID: 8672458

Stafford JA, **Veal JM**, Feldman PL, Valvano NL, Baer PG, Brackeen MF, Brawley ES, Connolly KM, Domanico PL, Han B, Rose DA, Rutkowske RD, Seskut L, Stimpson SA, Strickland AB, Verghese MW.

"Introduction of a conformational switching element on a pyrrolidine ring. Synthesis and evaluation of (R*,R*)-(+/-)-methyl 3-acetyl-4-[3- (cyclopentyloxy)-4-methoxyphenyl]-3-methyl-1-pyrrolidinecarboxylate, a potent and selective inhibitor of cAMP-specific phosphodiesterase." J Med Chem. 1995 Dec 22;38(26):4972-5. PMID: 8544172

Betts L, Josey JA, **Veal JM**, Jordan SR. "A nucleic acid triple helix formed by a peptide nucleic acid-DNA complex." Science. 1995 Dec 15;270(5243):1838-41. PMID: 8525381

Brackeen MF, Cowan DJ, Stafford JA, Schoenen FJ, **Veal JM**, Domanico PL, Rose D, Strickland AB, Verghese M, Feldman PL. "Design and synthesis of conformationally constrained analogues of 4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one (Ro 20-1724) as potent inhibitors of cAMP-specific phosphodiesterase." J Med Chem. 1995 Nov 24;38(24):4848-54. PMID: 7490734

J.M. Veal, and F.K. Brown, "Investigation of Thioformacetal Modified Nucleic Acids by Quantum Mechanics, Molecular Mechanics, and Molecular Dynamics.", J. Amer. Chem. Soc. 1995; 117(7), 1873-1880.

Brown SC, Thomson SA, **Veal JM**, Davis DG. "NMR solution structure of a peptide nucleic acid complexed with RNA." Science. 1994 Aug 5;265(5173):777-80. PMID: 7519361

J.M. Veal, X. Gao, and F.K. Brown, "A Comparison of DNA Oligomer Duplexes Containing Formacetal and Phosphodiester Linkers using Molecular Dynamics and Quantum Mechanics." J. Amer. Chem. Soc. 1993; 115(16), 7139-7145.

F.K. Brown and **J.M. Veal** , "A Quantum Mechanics Investigation of a DNA Oligomer Containing a Thioformacetal Linker", in *The Thirty-third Sanibel Symposium on Quantum Biology*, Wiley and Sons (1993), 48(20), 37-47.

Radhakrishnan, I., Patel, D., **Veal, JM**, and Gao, X., "Solution Conformation of a G.TA Triple in an Intramolecular Pyrimidine.Purine.Pyrimidine DNA Triplex." J. Amer. Chem. Soc. 1992; 114(17), 6913-6915.

Tanious FA, **Veal JM**, Buczak H, Ratmeyer LS, Wilson WD. "DAPI (4',6-diamidino-2-phenylindole) binds differently to DNA and RNA: minor-groove binding at AT sites and intercalation at AU sites." Biochemistry. 1992 Mar 31;31(12):3103-12. PMID: 1372825

Veal JM, Merchant K, Rill RL. "The influence of reducing agent and 1,10-phenanthroline concentration on DNA cleavage by phenanthroline + copper." Nucleic Acids Res. 1991 Jun 25;19(12):3383-8. PMID: 2062655

Veal JM, Wilson WD. "Modeling of nucleic acid complexes with cationic ligands: a specialized molecular mechanics force field and its application." J Biomol Struct Dyn. 1991 Jun;8(6):1119-45. PMID: 1716441

W.D. Wilson, Y. Li, and **J.M. Veal**, "NMR Analysis of Reversible Nucleic Acid - Small Molecule Complexes" in *Advances in DNA Sequence Specific Agents*, 1991, (Hurley, L., Ed.) JAI press, 112.

Veal JM, Rill RL. " Noncovalent DNA binding of bis(1,10-phenanthroline)copper(I) and related compounds." Biochemistry. 1991 Jan 29;30(4):1132-40. PMID: 1989681

Veal JM, Li Y, Zimmerman SC, Lamberson CR, Cory M, Zon G, Wilson WD. "Interaction of a macrocyclic bisacridine with DNA." *Biochemistry*. 1990 Dec 11;29(49):10918-27. PMID: 2271691

Clark GR, Brown DG, Sanderson MR, Chwalinski T, Neidle S, **Veal JM**, Jones RL, Wilson WD, Zon G, Garman E. "Crystal and solution structures of the oligonucleotide d(ATGCGCAT)₂: a combined X-ray and NMR study." *Nucleic Acids Res*. 1990 Sep 25;18(18):5521-8. PMID: 2216724

Veal JM, Rill RL. "Sequence specificity of DNA cleavage by bis(1,10-phenanthroline)copper(I): effects of single base pair transitions on the cleavage of preferred pyrimidine-purine-pyrimidine triplets." *Biochemistry*. 1989 Apr 18;28(8):3243-50. PMID: 2545253

Veal JM, Rill RL. "Sequence specificity of DNA cleavage by bis(1,10-phenanthroline)copper(I)." *Biochemistry*. 1988 Mar 22;27(6):1822-7. PMID: 3378032

Presentations, Invited Talks, and Lectures.

J. Partridge, A. Barabasz, T. Barta, P. Fadden, B. Foley, T. Freed, P. Hughes, S. Hall, M. Hu, H. Huang, W. Ma, A. Ommen, J. Rice, A. Scott, M. Silinski, E. Smith, P. Steed, **J. Veal**, A. Woodward. "Slow, tight binding inhibition of Hsp90 isoforms correlates with potent anti-proliferative activity in cancer cell lines" 2008 AACR National Meeting.

J. Rice, P. Fadden, K. Huang, A. Barabasz, B. Foley, **J. Veal**, P. Steed, S. Hall. "Biological effects of the novel small molecule Hsp90 inhibitor SNX-2112 as a single agent and in combination with Erlotinib in non-small cell lung cancer models" 2008 AACR National Meeting.

S. Hall, **J. Veal**, P. Steed, K. Huang, P. Fadden, J. Rice, A. Barabasz, B. Foley, M. Hu, J. Partridge, A. Scott, M. Silinski, S. Mabbett, L. DuBois, T. Freed, A. Ommen, E. Smith, P. Hughes, A. Woodward, S. McCall, T. Barta, W. Ma, M. Lewis, J. Otto, B. Pronk, G. Hanson, C. Markworth, L. Hinkley, M. Jenks, L. Geng, J. Eaves, J. Strachan, K. Verleysen. "Discovery and pre-clinical profile of SNX-5422: an orally active Hsp90 inhibitor in phase 1 trials for solid and hematological tumors", 2008 AACR National Meeting.

J. Veal, A. Barabasz, T. Barta, L. Dubois, J. Eaves, P. Fadden, B. Foley, T. Freed, L. Geng, S. Hall, G. Hanson, L. Hinkley, M. Hu, K. Huang, W. Ma, J. Otto, J. Partridge, B. Pronk, J. Rice, A. Scott, M. Silinski, P. Steed. "Application of Chemoproteomics Technology to the Discovery of Small Molecule Inhibitors of Hsp90", 2007 ACS-AACR Special Conference: Chemistry in Cancer Research a Vital Partnership, San Diego, CA.

S. Hall, A. Barabasz, T. Barta, L. DuBois, J. Eaves, P. Fadden, B. Foley, T. Freed, G. Hanson, L. Hinkley, M. Hu, M. Jenks, M. Lewis, W. Ma, J. Partridge, B. Pronk, J. Rice, A. Scott, M. Silinski, J. Strachan, P. Steed, **J. Veal**, K. Verleysen. "Chemoproteomics-driven drug discovery: identification of novel Hsp90 inhibitors", 2007 AACR National Meeting.

S. Hall, A. Barabasz, T. Barta, L. DuBois, J. Eaves, P. Fadden, B. Foley, T. Freed, G. Hanson, L. Hinkley, M. Hu, M. Jenks, M. Lewis, W. Ma, J. Partridge, B. Pronk, J. Rice, A. Scott, M. Silinski, J. Strachan, P. Steed, **J. Veal**, K. Verleysen. "Discovery in Parallel: Simultaneous Hit and Target Identification", 2007 IBC's 12th Annual World Congress Drug Discovery & Development of Innovative Therapeutics Conference, Boston, MA.

J. Veal, A. Barabasz, T. Barta, J. Eaves, P. Fadden, B. Foley, T. Freed, L. Geng, S. Hall, G. Hanson, L. Hinkley, M. Hu, H. Huang, W. Ma, J. Otto, J. Partridge, B. Pronk, J. Rice, A. Scott, M. Silinski, P. Steed. "Discovery of Small Molecule Inhibitors of Hsp90", 2006 AACR special conference - Drugging the Cancer Genome: Developing Rational Combination Therapies for Multigene Cancers, Rancho Mirage, California.

P. Steed, A. Barabasz, T. Barta, J. Eaves, P. Fadden, T. Freed, B. Foley, S. Hall, M. Hu, H. Huang, P. Hughes, A. Ommen, J. Otto, J. Partridge, J. Rice, A. Scott, M. Silinski, E. Smith, A. Woodward, **J. Veal**. "SNX-2112: A Novel, Selective, Potent Small Molecule Inhibitor of Hsp90 with Unique Pharmacodynamic Properties", 2006 18th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Prague, Czech Republic.

P. Fadden, A. Barabasz, T. Barta, J. Eaves, T. Freed, B. Foley, S. Hall, M. Hu, H. Huang, P. Hughes, A. Ommen, J. Otto, J. Partridge, J. Rice, A. Scott, M. Silinski, E. Smith, P. Steed, A. Woodward, **J. Veal**. "Discovery of Small Molecule Inhibitors of Hsp90", 2006 3rd International Conference on The Hsp90 Chaperone Machine in Monastery Seon, Germany.

P. Fadden, A. Barabasz, T. Barta, J. Eaves, B. Foley, L. Geng, S. Hall, G. Hanson, H. Huang, J. Otto, B. Pronk, J. Rice, **J. Veal**. "A novel, orally active, small molecule Hsp90 inhibitor", 2006 AACR National Meeting.

S. Hall, A. Barabasz, T. Barta, L. DuBois, J. Eaves, P. Fadden, B. Foley, T. Freed, G. Hanson, L. Hinkley, M. Hu, M. Jenks, M. Lewis, W. Ma, J. Partridge, B. Pronk, J. Rice, A. Scott, M. Silinski, J. Strachan, P. Steed, **J. Veal**, K. Verleysen. "From Library to Candidate: A Chemoproteomics Approach to Novel, Orally Active Hsp90 Inhibitors", 2006 Cambridge Healthtech Institute 6th Annual Chemogenomics Conference, Boston, MA.

J. Veal, A. Barabasz, T. Barta, J. Eaves, P. Fadden, B. Foley, T. Freed, L. Geng, S. Hall, G. Hanson, L. Hinkley, M. Hu, H. Huang, W. Ma, J. Otto, J. Partridge, B. Pronk, J. Rice, A. Scott, M. Silinski, P. Steed. "Discovery and Optimization of Highly Selective Hsp90 Inhibitors Using Chemoproteomics", 2005 Discovery on Target Conference, Boston, MA.

R. Kumar, C.G. Miller, J.H. Johnson, R.M. Crosby, T.M. Hopper, W. Liu, A.H. Epperly, R.G. Davis-Ward, P.A. Harris, R.A. Mook, Jr., **J.M. Veal**, J.A. Stafford and D.K. Luttrell. "An orally active inhibitor of VEGF receptor tyrosine kinase with potent anti-tumor activity", 2001 AACR National Meeting.

Davis, S., Edelstein, M.P.; Murray, D.M.; **Veal, J.M.**; Harris, P.L; Hunter, B.N.; Dickerson, S.; Frye, S.V.; Lackey, K.E.; Shewchuk, L.M.; Hassell, A.M.; Holmes, B.D.; Kuyper, L.F.; Rocque, W.J.; Dold, K.M. "The discovery of GW328510X for preventing chemotherapy-induced alopecia", 2000 AACR National Meeting.

S. Davis, K. Dold, M. Edelstein, D. Murray, D. Walker, **J. Veal**, M. Luzzio, P. Harris, R. Hunter, S. Dickerson, S. Frye, K. Lackey, L. Shewchuk, A. Hassell, W. Holmes, W. Rocque, B. Lovejoy, L. Kuyper. "Novel Cyclin-Dependent Kinase Inhibitors prevent Chemotherapy-Induced Alopecia", 2000 Keystone Symposia on Cancer, Cell Cycle and Therapeutics.

Veal, J., Bramson, N., Dickerson, S., Frye, S. V., Harris, P., Hassell, A. M., Holmes, W., Hunter, R., Kuyper, L., Lackey, K., Lovejoy, B., Luzzio, M. Montana, V., Rocque, W., Shewchuk, L., and Walker, D., "Identification of Inhibitors of Cyclin Dependent Kinases", Symposium on Cell Cycle, 1999 ACS National Meeting, New Orleans, Louisiana.

Luzzio, M. J., Bramson, N., Dickerson, S., Frye, S. V., Harris, P., Hassell, A. M., Holmes, W., Hunter, R., Kuyper, L., Lackey, K., Lovejoy, B., Montana, V., Rocque, W., Shewchuk, L., **Veal, J.**, and Walker, D. "Inhibitors of Cyclin Dependent Kinases: Design, Synthesis & Evaluation", 1999 AACR National Meeting.

J.M. Veal, Seminar "Use of Structure Assisted Drug Design in the Pharmaceutical Industry", Duke University, 1998.

J.M. Veal, Seminar "Computational Chemistry Techniques in the Design of Kinase Inhibitors", Duke University, 1998.

J.M. Veal and F.K. Brown, "A Comparison of DNA and RNA Oligomer Duplexes Containing Formacetal, Thioformacetal, and Phosphodiester Linkers", 1998 ACS National Meeting, Dallas, Texas.

J.M. Veal, Seminar "Structure Assisted Drug Design - Kinases as an Example", University of North Carolina at Chapel Hill, Linberger Center for Cancer, 1997.

J.M. Veal, Lecture on Nucleic Acid Conformation and Structural Properties at University of North Carolina at Chapel Hill, 1995-1997.

J.M. Veal and S.C. Brown, "Molecular Modeling of Peptide Nucleic Acid Duplexes and Triplexes", *IBC Conference on Rational Drug Design*, 1994.

J.M. Veal, Lecture on Nucleic Acid Conformation and Structural Properties at University of North Carolina at Chapel Hill, 1994.

F.K. Brown and **J.M. Veal**, "A Quantum Mechanics Investigation of a DNA Oligomer Containing a Thioformacetal Linker", in *The Thirty-third Sanibel Symposium on Quantum Biology*, 1993.

J.M. Veal, Lecture on Nucleic Acid Conformation and Structural Properties at University of North Carolina at Chapel Hill, 1993.

J.M. Veal, Y. Li, S.C. Zimmerman, C.R. Lamberson, M. Cory, and W.D. Wilson, "The Interaction of a Macrocyclic Bisacridine with DNA", *SUNY Conference on Biomolecular Structure and Dynamics*, (1991).

F.A. Tanious, **J.M. Veal**, H. Buczak, L.S. Ratmeyer and W.D. Wilson, "DAPI (4',6-Diamidino-2-Phenylindole) Binding to DNA and RNA", *Annual Meeting of the Biophysical Society*, (1990).

J.M. Veal and W.D. Wilson, "A Specialized Molecular Mechanics Force Field for Modeling of Nucleic Acid Complexes with Cationic Ligands", *Annual Meeting of the Biophysical Society*, (1990).

J.M. Veal and R.L. Rill, "Non-Covalent DNA Binding of Bis-(1,10-phenanthroline) copper(I) and Related Compounds", *SUNY Conference on Biomolecular Structure and Dynamics*, (1990).

J.M. Veal and R.L. Rill, "Sequence Specificity of DNA Cleavage by Bis-(1,10-phenanthroline) copper(I): Effects of Single Base Pair Transitions on the Cleavage of Preferred Pyrimidine-Purine-Pyrimidine Triplets", *Annual Meeting of the Biophysical Society*, (1989).

J.M. Veal and R.L. Rill, "Sequence Specificity of DNA Cleavage by Bis-(1,10-phenanthroline) copper(I)", *Annual Meeting of the Biophysical Society*, (1988).